CD47/SIRP alpha biochemical HTRF binding assay | Cisbio
A) CD47-SIRPɑ interaction blocks macrophage phagocytosis of cancer... | Download Scientific Diagram
2021 Jeffrey M. Hoeg Award Lecture: Defining the Role of Efferocytosis in Cardiovascular Disease: A Focus on the CD47 (Cluster of Differentiation 47) Axis | Arteriosclerosis, Thrombosis, and Vascular Biology
JCI - Oncogenic KRAS signaling drives evasion of innate immune surveillance in lung adenocarcinoma by activating CD47
CD47 - an overview | ScienceDirect Topics
CD47: the next checkpoint target for cancer immunotherapy - ScienceDirect
Frontiers | Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
063CE: Anti-CD47 Testing Interference with Connie Westhoff -
Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma | Haematologica
Human lung adenocarcinoma CD47 is upregulated by interferon-γ and promotes tumor metastasis: Molecular Therapy - Oncolytics
Regulation of CD47 expression in cancer cells - ScienceDirect
Targeting CD47 for cancer immunotherapy | Journal of Hematology & Oncology | Full Text
CD47-related Signaling Pathways & Research Progress on the Relationship with Related Diseases (Part Two) – Creative Biolabs Blog
CD47/SIRPα pathway mediates cancer immune escape and immunotherapy
CD47 — Wikipédia
Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphoma: Cell
Localized CD47 blockade enhances immunotherapy for murine melanoma | PNAS
Monoclonal anti‐CD47 interference in red cell and platelet testing - Velliquette - 2019 - Transfusion - Wiley Online Library
Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells | Nature Communications
Cells | Free Full-Text | Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma
CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis | Nature
The Antitumor Activities of Anti-CD47 Antibodies Require Fc-FcγR interactions | bioRxiv
SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy: Trends in Immunology
